Recce Pharmaceuticals Ltd (ASX:RCE)
Australia · Delayed Price · Currency is AUD 0.3550
-0.0050 (-1.39%)
Sep 2, 2026, 1:32 PM AEST
Recce Pharmaceuticals Balance Sheet
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Assets
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Cash & Equivalents | 2.69 | 10.45 | 4.42 | 1.56 | 11.58 |
Short-Term Investments | - | 0.24 | - | - | - |
Cash & Short-Term Investments | 2.69 | 10.69 | 4.42 | 1.56 | 11.58 |
Cash Growth | -74.78% | 142.02% | 182.74% | -86.52% | -44.51% |
Accounts Receivable | 3.87 | - | - | - | - |
Other Receivables | - | 0.2 | 0.16 | 0.09 | 0.18 |
Receivables | 3.87 | 0.2 | 0.16 | 0.09 | 0.18 |
Other Current Assets | 0.55 | 0.5 | 0.56 | 0.3 | 0.42 |
Total Current Assets | 7.12 | 11.39 | 5.14 | 1.95 | 12.18 |
Property, Plant & Equipment | 1.41 | 1.03 | 1.23 | 0.61 | 0.44 |
Other Intangible Assets | - | 0 | 0 | - | 0 |
Total Assets | 8.53 | 12.41 | 6.37 | 2.56 | 12.62 |
Liabilities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Accounts Payable | 12.57 | 2.18 | 3.97 | 0.95 | 0.48 |
Accrued Expenses | 0.85 | 0.93 | 0.57 | 0.41 | 0.38 |
Short-Term Debt | - | - | 9.69 | 3.05 | - |
Current Portion of Long-Term Debt | - | 1.53 | - | - | - |
Current Portion of Leases | 0.23 | 0.22 | 0.22 | 0.15 | 0.07 |
Other Current Liabilities | 2.68 | 1.27 | 0.62 | 0.29 | 1.51 |
Total Current Liabilities | 16.32 | 6.13 | 15.07 | 4.85 | 2.45 |
Long-Term Debt | - | 8.6 | - | - | - |
Long-Term Leases | 0.44 | 0.42 | 0.59 | 0.1 | - |
Pension & Post-Retirement Benefits | 0.19 | 0.32 | 0.24 | 0.19 | 0.12 |
Other Long-Term Liabilities | 8.3 | 0 | -0 | - | 0 |
Total Liabilities | 25.25 | 15.47 | 15.89 | 5.14 | 2.56 |
Shareholders' Equity
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Common Stock | 81.73 | 81.5 | 54.84 | 44.11 | 43.97 |
Retained Earnings | -101.32 | -91.5 | -70.08 | -55.54 | -42.46 |
Comprehensive Income & Other | 2.87 | 6.95 | 5.71 | 8.83 | 8.55 |
Shareholders' Equity | -16.72 | -3.05 | -9.52 | -2.59 | 10.06 |
Total Liabilities & Equity | 8.53 | 12.41 | 6.37 | 2.56 | 12.62 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Total Debt | 0.67 | 10.77 | 10.5 | 3.3 | 0.07 |
Net Cash (Debt) | 2.03 | -0.08 | -6.09 | -1.74 | 11.51 |
Net Cash Growth | - | - | - | - | -44.53% |
Net Cash Per Share | 0.01 | -0.00 | -0.03 | -0.01 | 0.07 |
Filing Date Shares Outstanding | 289.65 | 288.37 | 231.61 | 196.83 | 178.02 |
Total Common Shares Outstanding | 289.65 | 288.37 | 203.99 | 178.25 | 177.65 |
Working Capital | -9.21 | 5.26 | -9.93 | -2.9 | 9.74 |
Book Value Per Share | -0.06 | -0.01 | -0.05 | -0.01 | 0.06 |
Tangible Book Value | -16.72 | -3.05 | -9.52 | -2.59 | 10.06 |
Tangible Book Value Per Share | -0.06 | -0.01 | -0.05 | -0.01 | 0.06 |
Machinery | - | 0.95 | 0.92 | 0.79 | 0.74 |